Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored ...
A new survey from The Mesothelioma Center at Asbestos.com highlights growing selectivity in surgical recommendations while keeping surgery on the table for certain pleural mesothelioma patients.
The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback